Topics

Ebola

Emergent BioSolutions lands $22 million order to make Zika vaccine candidate

Emergent BioSolutions lands $22 million order to make Zika vaccine candidate

Emergent BioSolutions, a Gaithersburg-based drug developer, has received a federal task order worth up to $22 million to develop and manufacture a possible vaccine for the Zika virus, the mosquito-borne illness that is spreading rapidly through Central and South America.

The contract, from the federal Biomedical Advanced Research and Development Authority, calls for Emergent to develop and manufacture Zika vaccine candidates for Phase 1 clinical trials with humans. The base value of the 30-month contract is $17.9 million and it can be extended to $21.9 million.

Emergent will further develop a base vaccine candidate from BARDA, then manufacture it. BARDA is within the U.S....

73°